Announcements Trials
Browse Landscape

Phase

Phase 3 24Phase 2 22Phase 1 11Phase 1/2 7Phase 2/3 2

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Gastrointestinal 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Colonic Neoplasms 1

Interventions

Cisplatin 14Carboplatin 12Magnetic Resonance Spectroscopy 11Specimen Handling 10Gemcitabine 10pembrolizumab 8Pemetrexed 8atezolizumab 7Paclitaxel 7Radiotherapy, Intensity-Modulated 5Platinum 5Nivolumab 5Immunoglobulin G 5Doxorubicin 5Docetaxel 5Disulfides 5Bevacizumab 5130-nm albumin-bound paclitaxel 51,2-diaminocyclohexaneplatinum II citrate 5Cetuximab 4Biopsy 4durvalumab 3Temozolomide 3Standard of Care 3Rituximab 3Drug Therapy 3Dexamethasone 3Cyclophosphamide 3(225)Ac-DOTA-c(RGDyK) 3venetoclax 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Oxaliplatin × 30 days × Clear all
NCT05139017 2026-06-04

waveLINE-003

Merck Sharp & Dohme LLC

Phase 2/3 Recruiting
290 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT07462143 2026-05-22

A Phase â…¡/â…¢ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer

RemeGen Co., Ltd.

Phase 2/3 Recruiting
80 enrolled
Gastrointestinal

Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡